Evidence map›Paper›PMID 40488356›Full record

ArticleNeuropathology and applied neurobiology2025

MYL1-Related Congenital Myopathy: Clinical, Genetic and Pathological Insights.

Irene Madrigal, Cristina Villar-Vera, Gemma Arca, Jesica Expósito-Escudero, Laia Rodríguez-Revenga, Andres Piolatti-Luna, Nuria Muelas, Roger Vilchez, Maria Ciutad Celdran, Anna Codina and 10 more

Abstract readCase Reports
In one paragraph

Article in Neuropathology and applied neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Irene MadrigalBiochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Cristina Villar-VeraDepartment of Paediatrics, Hospital Clinico Universitario de Valencia, Valencia, Spain.
Gemma ArcaBiochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Jesica Expósito-EscuderoNeuromuscular Unit, Hospital Sant Joan de Déu, Barcelona, Spain.
Laia Rodríguez-RevengaBiochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Andres Piolatti-LunaDepartment of Paediatrics, Hospital Clinico Universitario de Valencia, Valencia, Spain.
Nuria MuelasCIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-2349-7481
Roger VilchezCIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Maria Ciutad CeldranDepartment of Neonatology, BCNatal, Hospital Clinic Barcelona, Barcelona, Spain.
Anna CodinaApplied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Berta Estévez-AriasNeuromuscular Unit, Hospital Sant Joan de Déu, Barcelona, Spain.
Laura Carrera-GarciaNeuromuscular Unit, Hospital Sant Joan de Déu, Barcelona, Spain.
Carlos OrtezNeuromuscular Unit, Hospital Sant Joan de Déu, Barcelona, Spain.
Leonardo Rodriguez-CarunchioDepartment of Pathology, Hospital Clinic, Barcelona, Spain.
Giorgia SebastianiDepartment of Neonatology, BCNatal, Hospital Clinic Barcelona, Barcelona, Spain.
Inmaculada AzorinCIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Andrés NascimentoCIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Cristina JouCIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Juan Jesus VilchezCIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-0532-2872
Daniel Natera-de BenitoNeuromuscular Unit, Hospital Sant Joan de Déu, Barcelona, Spain.ORCID 0000-0001-7764-2085

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2021SGR01492Agència de Gestió d'Ajuts Universitaris i de Recerca 2024 FI-1 00075Fundacion Isabel Gemio 2018/0200Fundación Mutua Madrileña AP171442019Instituto de Salud Carlos III CP22/00141Instituto de Salud Carlos III PI21/01532
6 · The paper itself

Abstract

Congenital myopathies and congenital muscular dystrophies encompass heterogeneous clinical and genetic groups of disorders characterised by muscle weakness with antenatal or early postnatal onset. These conditions are categorised according to distinctive myopathological features and causative genes. Despite advances in diagnosis through massive parallel sequencing and progress in understanding the underlying pathogenesis, many aspects of these disorders remain poorly understood. MYL1-related congenital myopathy is an ultra-rare and severe condition, associated with a deficiency of essential/alkali light myosin and impaired development of fast-twitch type II muscle fibres. This study aims to advance the understanding of the phenotype and pathogenesis of MYL1-congenital myopathy. We analysed the clinical characteristics of two individuals harbouring three novel variants in the MYL1 gene. We conducted detailed genomic analysis and extensive studies on their muscles using histological, immunohistochemical, immunofluorescence, Western Blot and electron microscopy. Both individuals showed a very severe congenital myopathy, characterised by congenital hypotonia and weakness, requiring ventilatory and nutritional assistance. Muscle biopsy revealed dystrophic-like or myopathic changes, with notable smallness of fast-twitch type II fibres, often arranged around larger type I fibres, drawing a floret pattern. These fibres expressed developmental myosin and exhibited features of aberrant myofibrillogenesis. Type I myofibres exhibited correct sarcomere alignment, but like the small fast-twitch fibres, both showed distorted cell organelles, vacuolar aggregates and membranous debris, indicating autophagic impairment. Our findings confirm that bi-allelic MYL1 variants are associated with a severe congenital myopathy, characterised by a distinctive clinical and histopathological phenotype involving impaired type II fibre development. Additionally, our study reveals a role for MYL1 in the organisation and trophism of all muscle fibre types. SUMMARY: MYL1 biallelic variants cause severe congenital myopathy with early hypotonia and type II fibre hypotrophy. Muscle biopsy shows a distinct pattern, including floret-like fibre arrangement. Findings suggest a broader role for MYL1 in fibre organisation and autophagy across muscle fibre types.

Indexed as

Myopathies, Structural, CongenitalMyosin Light ChainsMyotonia CongenitaHumansMuscle, SkeletalPhenotypeMyosin Light Chainscongenital muscular dystrophycongenital myopathyessential/alkali myosin light chainfast‐twitch type II muscle fibresmuscle cell autophagymyosin heavy chain

Identifiers

PMID40488356
PMCPMC12147433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.